spotlightOzempic, Wegovy and Mounjaro: Why Ireland is struggling to fund the new weight-loss drugsNew weight-loss drugs promise transformative benefits, but soaring demand and massive cost projections leave Ireland facing difficult funding choices
companiesCork operations of Eli Lilly underpin Ozempic maker Novo Nordisk's dwindling market dominance
comment-analysisTrump’s global tariff agenda puts Ireland’s pharmaceutical industry at serious risk